Immunomodulatory News and Research

RSS

Researchers develop new isolated limb infusion method for melanoma treatment

Worldwide, the incidence rates of skin cancer, like other types of cancer, is increasing. People in Europe and the Nordic countries are, compared to other areas of the world, at a higher risk of developing skin cancer due to their predominantly light and sun-sensitive skin type. The number of new cases of cancer in Estonia and Nordic countries has reached the same level as in sunny Australia, New Zealand and Florida. The increasing trend among Estonians to travel to southern counties is also likely to play a role in this.

27 Jan 2020

New standards needed for improving the design of clinical trials for MS patients

How can the perspectives of patients with multiple sclerosis (MS) be given more consideration in clinical trials? This question was investigated and corresponding recommendations were developed by a working group of the Drug Commission of the German Medical Association, the Charité University Hospital Berlin, and the Institute for Quality and Efficiency in Health Care.

17 Dec 2019

New combination therapy can lead to durable responses in patients with multiple myeloma

An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

17 Dec 2019

Breakthrough research develops novel vaccine poised to cure peanut allergies

Peanut allergies could become a thing of the past as breakthrough research from the University of South Australia develops a radically novel vaccination that's poised to cure the potentially life threatening condition.

6 Dec 2019

$Novel agent opens up new treatment option for patients with refractory myeloma$

Novel agent opens up new treatment option for patients with refractory myeloma

A novel agent called Selinexor has opened up new options for the treatment of patients with refractory myeloma. This was the conclusion of a major international clinical trial in which also the Karl Landsteiner University of Health Sciences in Krems, Austria participated.

6 Dec 2019

BrainStorm publishes NurOwn ALS Phase 2 randomized clinical trial results in Neurology

BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.

20 Nov 2019

Cancer patients with RA treated with immune checkpoint inhibitors likely to experience a flare

A new study found that cancer patients with a pre-existing autoimmune disease receiving immune checkpoint inhibitors as treatment are likely to experience a flare.

11 Nov 2019

New cannabis-based drug shows promise for pancreatic cancer

Cancer of the pancreas is a particularly deadly cancer, claiming over 90% of its victims within 5 years from diagnosis. It resists most standard therapies, including surgery, chemotherapy, radiation therapy, immunotherapy and targeted therapy, and metastasizes early, often before being diagnosed. A cure is possible only with very localized tumors.

22 Aug 2019

Study finds new way to help cancer doctors predict blood clots in patients with multiple myeloma

New research from the Hutchinson Institute for Cancer Outcomes Research- which is based at Fred Hutchinson Cancer Research Center- along with the University of Washington and the Seattle Cancer Care Alliance, identifies a simple way to help cancer doctors caring for patients with multiple myeloma to predict blood clots in order to take preventive action.

19 Jul 2019

$FDA grants accelerated approval to new treatment for refractory multiple myeloma$

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

3 Jul 2019

Endogenous retrovirus type W found to be a major contributor to nerve damage in MS

Early disease stages of MS are primarily characterized by immune cell infiltration of the CNS. This causes inflammation that damages the so-called myelin sheaths.

28 Jun 2019

Complement system shown to remove dead cells in retinitis pigmentosa, contradicting previous research

Researchers have found that the complement system seems to protect against retinal degeneration in retinitis pigmentosa.

18 Jun 2019

UAB researchers awarded $2.3 million grant to study macrophage circadian rhythms in heart failure

Researchers at the University of Alabama at Birmingham have been awarded a four-year, $2.3 million grant from the National Heart, Lung and Blood Institute to study macrophage circadian rhythms in heart failure.

13 Jun 2019

Research reveals immunomodulatory role of ent-kaurane diterpenoids toward NK cells

As early responders in the surveillance of malignant cells, natural killer cells play a significant role in the control of transformed cells at the tumor initiation stage through direct cytolysis. For this reason, NK cell-based immunotherapy is a potential therapeutic strategy for tumor sufferers.

31 May 2019

Angiotensin receptor blockers could improve response to cancer immunotherapy

A research team led by investigators at Massachusetts General Hospital and the Massachusetts Institute of Technology has found that combining a specialized version of an antihypertension drug with immune checkpoint blockers could increase the effectiveness of cancer immunotherapies.

30 Apr 2019

DNA rearrangement may predict poor outcomes in multiple myeloma

A certain type of DNA marker predicts poor outcomes in multiple myeloma, researchers at Winship Cancer Institute, Emory University have found.

24 Apr 2019

Study reveals immune evasion strategy developed by cytomegaloviruses

Owl monkey cytomegalovirus produces a decoy molecule A43 to evade detection and destruction by immune cells in their hosts, according to a study published April 4 in the open-access journal PLOS Pathogens by Ana Angulo of the University of Barcelona, and colleagues.

8 Apr 2019

Nanovaccine boosts immunity in mice with gut microbiome-mediated metabolic syndrome

A new class of biomaterial developed by Cornell researchers for an infectious disease nanovaccine effectively boosted immunity in mice with metabolic disorders linked to gut bacteria - a population that shows resistance to traditional flu and polio vaccines.

29 Mar 2019

Research reveals how metabolites can be used to inhibit epigenetic mechanisms and treat MS

Understanding and mitigating the role of epigenetics (environmental influences that trigger changes in gene expression) in disease development is a major goal of researchers.

28 Feb 2019

Quanterix extends oncology footprint with accelerated launch of next gen SP-X platform and CorPlex validated 10-Plex

Quanterix announce launch of its Simoa SP-X Imaging and Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu of additional multiplex panels.

From Quanterix 10 Jan 2019